Inflammation and Prostate Cancer Development and Progression

炎症与前列腺癌的发生和进展

基本信息

  • 批准号:
    8096809
  • 负责人:
  • 金额:
    $ 16.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Data forming the foundation for a role for inflammation in prostate cancer comes from a variety of fields. Epidemiology studies show an increased incidence of prostate cancer associated with prostatitis and a decreased risk for individuals taking anti-inflammatory drugs. Notably, two-candidate familial prostate cancer genes code for proteins associated with the innate immune response, interferon inducible ribonuclease (RNASEL) and macrophage scavenger receptor-1 (MSR1). Also, the loss of glutathione S-transferase (GST) expression, which has been described in most prostate cancers, increases the susceptibility to mutations induced by oxygen radicals produced by inflammation. Further, inflammation induced prostatic intraepithelial atrophy (PIA) is hypothesized to be a precursor to the development of prostate cancer. Finally, IL-6 has been linked to prostate cancer growth. The multiplicity of associations between inflammation and prostate cancer are correlative but strongly implicate a relationship. Thus, establishment of models that will provide a system for defining mechanisms associated with inflammation-induced modulation of prostate cancer development and progression are needed. We have developed a genetically modified mouse model expressing a prostate specific model antigen,membrane bound ovalbumin (mOVA), prostate specific PTEN knockout generated by Cre/Loxp, and luciferase expression in prostate epithelial cells for imaging purposes (POETPTEN). The model was generated by crossing a prostate specific mOVA transgenic (POET-3) with the genetically modified PTEN knockout expressing luciferase (PTENfl/fl-luc). Preliminary data demonstrate in both POET-3 and POETPTEN demonstrate that inflammation is induced in both models. Studies in POET-3 show inflammation remains 84 days after initiation. Notably, significantly elevated prostate epithelial cell proliferation was observed in the inflamed prostate as late as the 84 day time point. Likewise, cytokine production remains elevated in the inflamed prostate 45 days after initiation, which is the latest evaluation time point. Because the prostate- specific PTEN null model represents various stages of prostate cancer progression, we are in a unique position to evaluate the impact of inflammation on disease progression in the combined POET-PTEN model. These data provide a basis for the hypothesis that prostate inflammation modulates tumor development and progression. Studies outlined in this application propose to characterize prostate inflammation in both a pre- neoplastic and a tumor environment and identify potential immunoregulatory elements present during inflammation. To this end the following specific aims are proposed: Aim 1. Characterize prostate cancer development and progression in the inflamed prostate; and Aim 2. Characterization of inflammatory cell infiltration during prostate inflammation in a pre-neoplastic (PTEN+/fl), tumor (PTENfllfl) and benign (PTEN+/+) mice. PUBLIC HEALTH RELEVANCE: The proposed studies introduce a novel model for evaluating the impact of inflammation on prostate cancer development. The studies proposed will determine the impact of inflammation on prostate cancer development and progression.
描述(由申请人提供):炎症在前列腺癌中作用的基础数据来自各个领域。流行病学研究表明,前列腺炎与前列腺癌的发病率增加有关,服用消炎药的人患前列腺癌的风险降低。值得注意的是,两个候选家族性前列腺癌基因编码与先天免疫应答相关的蛋白,干扰素诱导核糖核酸酶(RNASEL)和巨噬细胞清零受体-1 (MSR1)。此外,谷胱甘肽s -转移酶(GST)表达的缺失(在大多数前列腺癌中已被描述)增加了对炎症产生的氧自由基诱导的突变的易感性。此外,炎症诱导的前列腺上皮内萎缩(PIA)被认为是前列腺癌发展的前兆。最后,IL-6与前列腺癌的生长有关。炎症和前列腺癌之间的多重关联是相关的,但强烈暗示了一种关系。因此,需要建立模型,为定义炎症诱导的前列腺癌发生和进展的调节机制提供系统。我们开发了一种转基因小鼠模型,表达前列腺特异性模型抗原、膜结合卵清蛋白(mOVA)、Cre/Loxp产生的前列腺特异性PTEN敲除,以及用于成像目的的前列腺上皮细胞中荧光素酶的表达(POETPTEN)。通过将前列腺特异性mOVA转基因基因(POET-3)与表达荧光素酶的PTEN基因敲除基因(PTENfl/fl-luc)杂交产生模型。初步数据显示,在poet3和POETPTEN中,两种模型均可诱导炎症。在POET-3的研究显示炎症在起始84天后仍然存在。值得注意的是,炎症前列腺中前列腺上皮细胞增殖明显升高,直至84天时间点。同样,在开始治疗后45天,炎症前列腺细胞因子的产生仍然升高,这是最新的评估时间点。由于前列腺特异性PTEN零模型代表前列腺癌进展的各个阶段,我们在评估炎症对POET-PTEN联合模型中疾病进展的影响方面处于独特的地位。这些数据为前列腺炎症调节肿瘤发生和发展的假设提供了基础。本应用程序中概述的研究建议在肿瘤前和肿瘤环境中表征前列腺炎症,并确定炎症期间存在的潜在免疫调节因子。为此目的,提出了以下具体目标:目标1。表征前列腺癌的发展和进展在发炎的前列腺;和Aim 2。癌前(PTEN+/fl)、肿瘤(PTENfllfl)和良性(PTEN+/+)小鼠前列腺炎症期间炎症细胞浸润的特征

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Timothy L. Ratliff其他文献

Elevated Cyclic Adenosine 3′, 5′ Monophosphate Enhances Lactic Acid Production by <em>Streptococcus lactis</em>
  • DOI:
    10.3168/jds.s0022-0302(81)82584-2
  • 发表时间:
    1981-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Timothy L. Ratliff;Dwight E. Talburt
  • 通讯作者:
    Dwight E. Talburt
1861: Involvement of Growth Factors in the Process of Post-Vasectomy Micro-Recanalization
  • DOI:
    10.1016/s0022-5347(18)32034-2
  • 发表时间:
    2007-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Brandon C. Stahl;Timothy L. Ratliff;Barry R. De Young;Moshe Wald
  • 通讯作者:
    Moshe Wald
Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
病毒载体的比较:膀胱癌模型中的基因转移效率和组织特异性。
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    D. Siemens;S. Crist;J. Austin;J. Tartaglia;Timothy L. Ratliff
  • 通讯作者:
    Timothy L. Ratliff
UROLOGICAL SURVEYUro-Science
泌尿科检查Uro-Science
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Timothy L. Ratliff
  • 通讯作者:
    Timothy L. Ratliff
Suppressive Effects of Regional Lymph Node Cells and Extracts on Antibody-Dependent Cellular Cytotoxicity
  • DOI:
    10.1016/s0022-5347(17)57501-1
  • 发表时间:
    1978-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    William J. Catalona;Arlene T. Feldman;Timothy L. Ratliff;Robert E. Mccool
  • 通讯作者:
    Robert E. Mccool

Timothy L. Ratliff的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Timothy L. Ratliff', 18)}}的其他基金

T cell regulation by adult prostate stem cells
成体前列腺干细胞对 T 细胞的调节
  • 批准号:
    10382302
  • 财政年份:
    2021
  • 资助金额:
    $ 16.65万
  • 项目类别:
Impact of Inflammation on Adult Prostate Stem Cells
炎症对成体前列腺干细胞的影响
  • 批准号:
    10439754
  • 财政年份:
    2020
  • 资助金额:
    $ 16.65万
  • 项目类别:
Impact of Inflammation on Adult Prostate Stem Cells
炎症对成体前列腺干细胞的影响
  • 批准号:
    10218167
  • 财政年份:
    2020
  • 资助金额:
    $ 16.65万
  • 项目类别:
Impact of Inflammation on Adult Prostate Stem Cells
炎症对成体前列腺干细胞的影响
  • 批准号:
    10655549
  • 财政年份:
    2020
  • 资助金额:
    $ 16.65万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8681188
  • 财政年份:
    2013
  • 资助金额:
    $ 16.65万
  • 项目类别:
Use of Micro-RNA Arrays to Identify MDSC Functional Pathways and Markers
使用 Micro-RNA 阵列识别 MDSC 功能途径和标记
  • 批准号:
    8451031
  • 财政年份:
    2013
  • 资助金额:
    $ 16.65万
  • 项目类别:
Use of Micro-RNA Arrays to Identify MDSC Functional Pathways and Markers
使用 Micro-RNA 阵列识别 MDSC 功能途径和标记
  • 批准号:
    8601921
  • 财政年份:
    2013
  • 资助金额:
    $ 16.65万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8470548
  • 财政年份:
    2012
  • 资助金额:
    $ 16.65万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8182728
  • 财政年份:
    2010
  • 资助金额:
    $ 16.65万
  • 项目类别:
Inflammation and Prostate Cancer Development and Progression
炎症与前列腺癌的发生和进展
  • 批准号:
    8009233
  • 财政年份:
    2010
  • 资助金额:
    $ 16.65万
  • 项目类别:

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 16.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了